Nutex Health Inc.: Form 10-Q for the period ended Sep 30, 2020
Filed with the SEC on Nov 16, 2020 and accepted by EDGAR at Nov 16, 2020, 13:30 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-07-01 to 2020-09-30 | $350.0k | us-gaap:Revenues |
| Revenue | 9 months2020-01-01 to 2020-09-30 | $1.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2020-07-01 to 2020-09-30 | $210.9k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2020-01-01 to 2020-09-30 | $674.9k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-07-01 to 2020-09-30 | $139.1k | us-gaap:GrossProfit |
| Gross profit | 9 months2020-01-01 to 2020-09-30 | $519.4k | us-gaap:GrossProfit |
| Research and development | 3 months2020-07-01 to 2020-09-30 | $73.8k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2020-01-01 to 2020-09-30 | $503.0k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-07-01 to 2020-09-30 | −$628.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2020-01-01 to 2020-09-30 | −$3.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2020-07-01 to 2020-09-30 | $1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2020-01-01 to 2020-09-30 | $860.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-07-01 to 2020-09-30 | $0.34 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months2020-01-01 to 2020-09-30 | $0.18 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months2020-01-01 to 2020-09-30 | −$1.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2020-01-01 to 2020-09-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-09-30 | $27.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-09-30 | $233.1k | us-gaap:AssetsCurrent |
| Total assets | At period end2020-09-30 | $7.0m | us-gaap:Assets |
| Current liabilities | At period end2020-09-30 | $1.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-09-30 | $1.6m | us-gaap:Liabilities |
| Long-term debt | At period end2020-09-30 | $0 | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2020-09-30 | $5.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001607062-20-000329. Last ingested by Listed: Nov 14, 2026, 12:46 ET. Listed shows no prices and gives no investment advice.